Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

Bristol-Myers Squibb101 enrolled

Overview

This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days. The study will include 100 patients treated in different public centers in the Mexican Republic.

Study Type

OBSERVATIONAL

Enrollment

101

Conditions

Leukemia

Interventions

DasatinibDRUG

Eligibility

Sex: ALLMin age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women ≥15 years of age * Diagnosis of chronic myeloid leukemia in any phase that used dasatinib at any time between January 2008 and November 2014 * Have received dasatinib as part of their first-line or second-line treatment for at least 45 days Exclusion Criteria: * Patients who received dasatinib as part of any clinical trial * Patients who do not have complete data on the data collection sheet * Patients who do not have medical records available at the moment of the data verification

Outcomes

Primary Outcomes

Detect the absence and presence of pleural effusion in Mexican patients measured from the medical records and databases of each of the participating medical centers

Time frame: 1 year and 4 month of data collection

Secondary Outcomes

Establish the factors associated with response of the patients who develop pleural effusion

Factors: Hematological Response * Standardization of counts in peripheral blood with leukocytes \<10 × 10\^9 and platelets \<450 ×10\^9 * Absence of immature elements in the smear * Basophils \<5% * Absence of palpable splenomegaly Complete Molecular Response (CMR) Undetectable BCR-ABL mRNA transcripts by real time quantitative and/or nested Partial Cytogenetic Response (PCR) in two consecutive blood samples of adequate quality (sensitivity \>104) Major Molecular Response (MMR) Ratio of BCR-ABL to ABL (or other housekeeping genes) ≤0.1% on the international scale

Time frame: 1 year and 4 month of data collection

Main characteristics of the patients who develop pleural effusion

Characteristics: Age, gender, comorbidity

Time frame: 1 year and 4 month of data collection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.